Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Karyopharm Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $40.6 Mil. Karyopharm Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $166.2 Mil. Karyopharm Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $108.4 Mil. Therefore, Karyopharm Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -1.16.
Karyopharm Therapeutics Scaled Net Operating Assets Related Terms
Karyopharm Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Karyopharm Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Scaled Net Operating Assets Chart
KPTI vs CHRS, TARA, CNTN: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Karyopharm Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -1.16 mean?
Karyopharm Therapeutics (KPTI) has a Scaled Net Operating Assets of -1.16 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Scaled Net Operating Assets too high?
Karyopharm Therapeutics' current Scaled Net Operating Assets is -1.16. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Scaled Net Operating Assets compare to CHRS and TARA?
Karyopharm Therapeutics' Scaled Net Operating Assets of -1.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Scaled Net Operating Assets is -1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.77 — trading 52.9% above its estimated fair value. The current Scaled Net Operating Assets is -1.16. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Scaled Net Operating Assets is -1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of $9.77 is trading 52.9% above its estimated GF Value™ of $6.39.
GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.
Key valuation signals for KPTI:
Scaled Net Operating Assets: -1.16
GF Value™: $6.39 vs. price of $9.77 (52.9% above fair value)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score
Get the complete analysis for KPTI
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
